Report Feature
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global recombinant DNA technology market report, please download the report brochure.
The study includes trends and forecast for the global recombinant DNA technology market by product, component, application, end use, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Medical
- Therapeutic Agent
- Human Protein
- Vaccine
-
Non-Medical
- Biotech Crops
- Specialty Chemicals
- Others
By Component [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Expression System
- Mammalian
- Bacteria
- Yeast
- Baculovirus / Insects
- Others
- Cloning Vector
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
- Food & Agriculture
- Health & Diseases
- Humans
- Animals
- Environment
- Others
By End Use [Value ($ Million) shipment analysis for 2014 – 2025]:
- Biotechnology and Pharmaceutical Companies
- Academic & Government Research Institutes
- Others
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
-
North America
- United States
- Canada
- Mexico
-
Europe
- United Kingdom
- Germany
- Spain
- Italy
- France
-
Asia Pacific
- China
- Japan
- India
-
The Rest of the World
- Brazil
Some of the recombinant DNA technology companies profiled in this report include F. Hoffmann-La Roche, Profacgen, Amgen, Novartis, GenScript, Pfizer, Novo Nordisk, Biogen, Biocon, GlaxoSmithKline, New England Biolabs, Cibus, Monsanto Company, and Horizon Discovery Group.
Lucintel forecasts that medical will remain the largest product segment over the forecast period, as it has facilitated disease treatment by insertion of new genes in place of damaged & diseased genes.
Within this market, pharmaceutical & biotechnology companies will remain the largest end use segment over the forecast period, as the techniques accelerate their drug development capabilities. Moreover, the end products using rDNA techniques in this segment are highly valued and observed to have significant improvement in productivity.
North America will remain the largest region over the forecast period because the presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology have driven the regional growth.
|
Features of the Global Recombinant DNA Technology Market |
|
|
This report answers following key questions |
|
Q.1 What are some of the most promising potential, high-growth opportunities for the global recombinant DNA technology market by product (medical (therapeutic agent, human protein, and vaccine) and non-medical (biotech crops, specialty chemicals, and others), component (expression system (mammalian, bacteria, yeast, baculovirus / insects, and others) and cloning vector), application (food & agriculture, health & diseases (humans and animals), environment, and others), end-use (biotechnology and pharmaceutical companies, academic & government research institutes, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)? Q.2 Which segments will grow at a faster pace and why? Q.3 Which region will grow at a faster pace and why? Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global recombinant DNA technology market? Q.5 What are the business risks and threats to the global recombinant DNA technology market? Q.6 What are the emerging trends in this recombinant DNA technology market and the reasons behind them? Q.7 What are some changing demands of customers in this recombinant DNA technology market? Q.8 What are the new developments in this recombinant DNA technology market? Which companies are leading these developments? Q.9 Who are the major players in this recombinant DNA technology market? What strategic initiatives are being implemented by key players for business growth? Q.10 What are some of the competitive products and processes in this recombinant DNA technology market, and how big of a threat do they pose for loss of market share via material or product substitution? Q.11 What M&A activities did take place in the last five years in the global recombinant DNA technology market? |
| Key Features | Description |
| Base Year for Estimation | 2019 |
|
Trend Period (Actual Estimates) |
2014-2019 |
| Forecast Period | 2020-2025 |
| Pages | More than 150 |
| Market Representation / Units | Revenue in US $ Million |
| Report Coverage | Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling |
| Market Segments | Product (Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others), Component (Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insects, and Others) and Cloning Vector), Application (Food & Agriculture, Health & Diseases (Humans And Animals), Environment, and Others), and End Use (Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others) |
Regional Scope |
North America (USA, Mexico, and Canada), Europe (Germany, United Kingdom, Spain, Italy, and France), Asia (China, Japan, and India), and ROW (Brazil) |
| Customization | 10% Customization without Any Additional Cost |
Table of Contents
Methodology
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.